Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulness
Authors:
Open Access
- 8 October 2012
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 3 (6) , 287-300
Abstract
Schizophrenia and bipolar disorder are often highly debilitating with chronic courses, and psychotropic drugs represent cornerstones in the treatment. The primary aim of the review was to summarize the latest evidence with regards to the efficacy and effectiveness of drug treatment of schizophrenia and the manic phases of bipolar disorder. Schizophrenia systematic reviews conclude that antipsychotic drugs are effective in treating overall symptoms of psychosis and in preventing relapse. Some of the newer agents, the second-generation antipsychotics (SGAs), have demonstrated superiority compared with the older first-generation drugs and other SGAs but side-effect differences among the drugs are of a greater magnitude than effect differences. The pragmatic randomized trials of effectiveness have shown a longer time until treatment discontinuation for olanzapine compared with other antipsychotics. Cohort studies have found superiority for the long-acting injection formulations compared with the oral formulations of the drugs, and lower total mortality risk in users of antipsychotics compared with non-users. In bipolar mania SGAs have shown superior antimanic efficacy compared with other mood-stabilizing drugs. In conclusion antipsychotics, in particular some of the SGAs, seem to be drugs of first choice for both schizophrenia and bipolar mania. This perspective review focused on mean effects but the group means may not always be particularly useful as schizophrenia and bipolar mania are biologically heterogeneous disorders with large inter-individual variations in drug response and tolerance. In patients with a prior drug history the different pharmacological and clinical profiles may be exploited in subsequent choices of drugs.Keywords
This publication has 99 references indexed in Scilit:
- Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey InitiativeArchives of General Psychiatry, 2011
- Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysisSchizophrenia Research, 2010
- Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head ComparisonsSchizophrenia Bulletin, 2010
- Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidoneBMC Psychiatry, 2010
- The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary StatementsSchizophrenia Bulletin, 2009
- Preventing the Second Episode: A Systematic Review and Meta-analysis of Psychosocial and Pharmacological Trials in First-Episode psychosisSchizophrenia Bulletin, 2009
- The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common PathwaySchizophrenia Bulletin, 2009
- Antipsychotic Therapy During Early and Late Pregnancy. A Systematic ReviewSchizophrenia Bulletin, 2008
- Atypical antipsychotics in bipolar disorder: systematic review of randomised trialsBMC Psychiatry, 2007
- Methodological Issues in Current Antipsychotic Drug TrialsSchizophrenia Bulletin, 2007